OPT 302

Drug Profile

OPT 302

Alternative Names: OPT-302; soluble VEGFR-3; VGX 300

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vegenics
  • Developer Opthea
  • Class Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Phase I/II Diabetic macular oedema

Most Recent Events

  • 03 Jan 2018 Phase-I/II clinical trials in Diabetic macular oedema (Combination therapy, Treatment-experienced) in Australia and USA (Intravitreous)
  • 06 Nov 2017 Phase-II clinical trials in Wet age-related macular degeneration (Combination therapy, Treatment naive) in USA (Intravitreous) (NCT03345082)
  • 15 Aug 2017 Updated efficacy data from a phase I/II trial in Wet age related macular degeneration released by Opthea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top